SINOMED(SH:688108)2024-05-24 10:16Group 1: Product Offerings - The company currently offers two intracranial stent products: the drug-eluting stent system (NOVA) and the thrombectomy stent (GHUNTER), which meet clinical needs effectively [2] - The NOVA stent is designed for intracranial arterial lesions, improving lumen diameter and preventing restenosis [2] - The GHUNTER stent is intended for the removal of thrombus in large vessels within 8 hours of ischemic stroke onset [3] Group 2: Research and Development - The company is developing several neurointerventional products, including self-expanding stents and mesh stents, with details disclosed in the 2023 annual report [3] - The self-expanding intracranial drug-coated stent system has received special review approval from the National Medical Products Administration and is currently in the registration process [4] Group 3: Market Performance - In 2023, the company's coronary stent business saw a significant growth of 99.10% compared to the previous year, attributed to its first year participating in the national centralized procurement [3] - The total intended procurement volume for coronary stents is approximately 50,000 units, with over a thousand hospitals selecting the products [3] - The coronary stent sales volume increased nearly fivefold compared to the previous year, achieving record highs in both sales and hospital admissions [3] Group 4: Market Potential - The volume of coronary interventional surgeries in China has not yet reached the average levels of developed countries, indicating further growth potential in the domestic market [4] - The company’s innovative products are expected to enhance surgical safety and efficacy, particularly for atherosclerotic stenosis in intracranial arteries [4]